Literature DB >> 14985706

HIV vaccine design and the neutralizing antibody problem.

Dennis R Burton1, Ronald C Desrosiers, Robert W Doms, Wayne C Koff, Peter D Kwong, John P Moore, Gary J Nabel, Joseph Sodroski, Ian A Wilson, Richard T Wyatt.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14985706     DOI： 10.1038/ni0304-233

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  387 in total

1.  Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Authors:  Marit Kramski; Rob J Center; Adam K Wheatley; Jonathan C Jacobson; Marina R Alexander; Grant Rawlin; Damian F J Purcell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

3.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

Review 4.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

5.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

6.  Very few substitutions in a germ line antibody are required to initiate significant domain exchange.

Authors:  Michael Huber; Khoa M Le; Katie J Doores; Zara Fulton; Robyn L Stanfield; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

7.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

8.  Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.

Authors:  Michael J Caulfield; Vadim Y Dudkin; Elizabeth A Ottinger; Krista L Getty; Paul D Zuck; Robin M Kaufhold; Robert W Hepler; Georgia B McGaughey; Michael Citron; Renee C Hrin; Ying-Jie Wang; Michael D Miller; Joseph G Joyce
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

9.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 10.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.